

Press release

## PEP-Therapy appoints Hatem Azim, MD, PhD, as Chief Medical Officer

**Hatem brings over 20 years of experience in early to late-stage oncology clinical development in top tier biotech companies.**

---

**Paris (France), May 30, 2024 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, announced the appointment of Hatem Azim, MD, PhD, as Chief Medical Officer (CMO).**



Dr. Hatem Azim is a seasoned drug developer and brings more than 20 years of healthcare and biotech or pharmaceutical industry experience, having led the advancement of about fifteen of early to late-stage clinical drug development programs in oncology.

Before joining PEP-Therapy, Hatem was Chief Medical Officer at Emergence Therapeutics, recently acquired by Eli Lilly, where he played a key role in designing and running the clinical program for their antibody drug conjugate in solid tumors. Prior to this role, Hatem has held several senior positions in biotechnology and pharmaceutical companies, leading clinical drug development, including Head of early clinical development at Pierre Fabre and Vice President, Head of clinical development at Innate Pharma.

Hatem has also held several academic appointments including Medical Oncologist and Scientific Director at the Jules Bordet Institute in Brussels, Belgium and Adjunct Assistant Professor of Oncology at the American University of Beirut, Lebanon. He is still acting as a senior faculty at the college of the European School of Oncology and a consultant at the Cairo Cure Oncology Center, Egypt.

Hatem is highly published with more than 140 research papers and 10 book chapters. Hatem has served as member of several international guideline committees and has been invited as faculty member on numerous occasions including at the annual conferences of the European Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO). He is the recipient of several awards, including the ASCO Merit Award and the ESMO Translational Research Award.

**Antoine Prestat, CEO and co-founder of PEP-Therapy** said: *"We are excited to welcome Hatem at PEP-Therapy and to benefit from his strong experience in developing innovative drugs in oncology. He will play a pivotal role in advancing the clinical development of PEP-010, our lead asset currently evaluated in a Phase Ib trial in platinum-resistant ovarian cancer and pancreatic ductal adenocarcinoma. Hatem's appointment is timely as the company prepares its Phase II clinical plan and is in the process of structuring valuable long-term partnerships."*

**Hatem Azim, MD, PhD, CMO of PEP-Therapy**, added: *"I am delighted to be joining the talented PEP-Therapy team at this key inflection point in the company's evolution. I look forward to working with our clinical partners on the CLEVer-PEptide study and contributing to PEP-Therapy's strategy in oncology to bring innovative peptide-based agents to patients with significant unmet medical needs."*

xxx

### **About PEP-Therapy**

PEP-Therapy is a Paris-based clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology. PEP-010, lead drug candidate, is a pro-apoptotic agent currently evaluated in a Phase Ia/b clinical trial. The company also develops a pipeline of peptide-based products in oncology. Founded in 2014, PEP-Therapy builds on research from Sorbonne University and Institut Curie, and is backed by international investors: Seventure Partners (Quadrivium 1 Seed Fund), CapHorn, i&i Prague, Italian Angels for Growth (IAG), Doorway, Magna Capital Partners (MCP), Business Angels des Grandes Ecoles (BADGE), and Jérôme Majoie (former Managing Director of Laboratoires Fournier affiliates (USA, UK, Sweden, Japan), CEO of La Fondation Fournier-Majoie).

For more information, please visit [www.pep-therapy.com](http://www.pep-therapy.com).

### **Contacts**

#### **PEP-Therapy**

Antoine Prestat, CEO & co-founder

[hello.pep@pep-therapy.com](mailto:hello.pep@pep-therapy.com)

#### **ATCG Partners**

Marie Puvieux

[PEP-Therapy@atcg-partners.com](mailto:PEP-Therapy@atcg-partners.com)

+33 6 10 54 36 72